Relation of body fat indexes to vitamin D status and deficiency among obese adolescents

BACKGROUND: Data on the relation between vitamin D status and body fat indexes in adolescence are lacking. OBJECTIVE: The objective was to identify factors associated with vitamin D status and deficiency in obese adolescents to further evaluate the relation of body fat indexes to vitamin D status an...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of clinical nutrition Vol. 90; no. 3; pp. 459 - 467
Main Authors Lenders, Carine M, Feldman, Henry A, Von Scheven, Emily, Merewood, Anne, Sweeney, Carol, Wilson, Darrell M, Lee, Phillip DK, Abrams, Stephanie H, Gitelman, Stephen E, Wertz, Marcia S, Klish, William J, Taylor, George A, Chen, Tai C, Holick, Michael F
Format Journal Article
LanguageEnglish
Published Bethesda, MD American Society for Clinical Nutrition 01.09.2009
American Society for Nutrition
American Society for Clinical Nutrition, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BACKGROUND: Data on the relation between vitamin D status and body fat indexes in adolescence are lacking. OBJECTIVE: The objective was to identify factors associated with vitamin D status and deficiency in obese adolescents to further evaluate the relation of body fat indexes to vitamin D status and deficiency. DESIGN: Data from 58 obese adolescents were obtained. Visceral adipose tissue (VAT) was measured by computed tomography. Dual-energy X-ray absorptiometry was used to measure total bone mineral content, bone mineral density, body fat mass (FM), and lean mass. Relative measures of body fat were calculated. Blood tests included measurements of 25-hydroxyvitamin D [25(OH)D], parathyroid hormone (PTH), osteocalcin, type I collagen C-telopeptide, hormones, and metabolic factors. Vitamin D deficiency was defined as 25(OH)D < 20 ng/mL. PTH elevation was defined as PTH > 65 ng/mL. RESULTS: The mean (±SD) age of the adolescents was 14.9 ± 1.4 y; 38 (66%) were female, and 8 (14%) were black. The mean (±SD) body mass index (in kg/m²) was 36 ± 5, FM was 40.0 ± 5.5%, and VAT was 12.4 ± 4.3%. Seventeen of the adolescents were vitamin D deficient, but none had elevated PTH concentrations. Bone mineral content and bone mineral density were within 2 SDs of national standards. In a multivariate analysis, 25(OH)D decreased by 0.46 ± 0.22 ng/mL per 1% increment in FM (β ± SE, P = 0.05), whereas PTH decreased by 0.78 ± 0.29 pg/mL per 1% increment in VAT (P = 0.01). CONCLUSIONS: To the best of our knowledge, our results show for the first time that obese adolescents with 25(OH)D deficiency, but without elevated PTH concentrations, have a bone mass within the range of national standards (±2 SD). The findings provide initial evidence that the distribution of fat may be associated with vitamin D status, but this relation may be dependent on metabolic factors. This study was registered at www.clinicaltrials.gov as NCT00209482, NCT00120146.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
The contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
Supported by the Joel and Barbara Alpert Endowment for the Children of the City (CML), the NIH pilot feasibility project P30 DK46200 (CML) from the Boston Obesity Nutrition Research Center, K23 DK082732 (CML) from the NIDDK, and NIH grant MO1-RR00533 (Boston University School of Medicine, MFH). The Glaser Pediatric Research Network (GPRN) consists of five clinical research centers and a Data Coordinating Center (listed below) devoted to clinical research involving disorders important in pediatrics. The GPRN is funded by the Elizabeth Glaser Pediatric Research Foundation (EGPRF), a program of the Elizabeth Glaser Pediatric AIDS Foundation. The study was funded by the EGPRF and the NIH/NCRR (Stanford University: grant number MO1-RR00070; Baylor College of Medicine: grant number MO1-RR00188; University of California, San Francisco: UCSF-CTSI grant number UL1-RR024131; University of California, Los Angeles: grant number MO1-RR00865; Harvard Medical School: Children's Hospital Boston grant number MO1-RR02172). Bristol-Myers Squibb generously provided active drug and placebo for the subsequent intervention phase of the study.
ISSN:0002-9165
1938-3207
1938-3207
DOI:10.3945/ajcn.2008.27275